2.1
Pembrolizumab (Keytruda, Merck Sharp & Dohme) plus carboplatin and paclitaxel or nab-paclitaxel is indicated for 'the first-line treatment of metastatic squamous non-small-cell lung carcinoma in adults'.
2 Information about pembrolizumab plus carboplatin and paclitaxel or nab-paclitaxel
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for pembrolizumab.
Price
2.3
Pembrolizumab solution for infusion costs £2,630 per 100‑mg vial (excluding VAT; BNF online, accessed August 2021).
2.4
The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.